Johnson & Johnson
Jul 25, 2014
Oncology Therapeutics Making Big in Coming Years
The industry's 10 biggest-selling cancer drugs generated combined sales of $37.4billion in 2013, with Roche's Rituxan, Avastin and Herceptin franchises extending their lead at the top of this league table. With combined sales of around $21 billion, these three drugs alone accounted for approximately 56 percent of t...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
